Position history for UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC's holdings in CRINETICS PHARMACEUTICALS IN
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC holds 225,842 shares of CRNX (CRINETICS PHARMACEUTICALS IN), worth $10.5M as of 2025-Q4. The position was increased (++3.7% shares). CRNX represents 0.0% of UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC's portfolio.
Current Value
$10.5M
Current Shares
225,842
Total Value Change
-$1.2M
Total Shares Change
-35,138
Other major holders of CRNX: BNP PARIBAS FINANCIAL MARKETS, FMR LLC, VANGUARD GROUP INC
Increased |
| 225,842 |
+3.7% |
| $10.5M |
| 0.0% |
| $47.39 |
29 |
| 2025-Q3 | Decreased | 217,690 | -35.0% | $9.1M | 0.0% | $43.51 | 0 |
| 2025-Q2 | Decreased | 334,796 | -3.7% | $9.6M | 0.0% | $29.96 | 0 |
| 2025-Q1 | Increased | 347,581 | +6.9% | $11.7M | 0.0% | $34.73 | 30 |
| 2024-Q4 | Increased | 325,276 | +19.7% | $16.6M | 0.0% | $50.67 | 33 |
| 2024-Q3 | Increased | 271,747 | +4.1% | $13.9M | 0.0% | $50.75 | 29 |
| 2024-Q2 | Increased | 260,980 | +23.2% | $11.7M | 0.0% | $44.79 | 34 |